Download Plant Made Biopharmaceuticals: Next

Plant Made Biopharmaceuticals
NEXT-GENERATION THERAPEUTICS
FOR ORPHAN DISEASES
PLANT MADE
BIOPHARMACEUTICALS:
OUR ASSET, YOUR
ADVANTAGE
We at Greenovation work to
advance the development of new
treatments that improve quality of
life in patients suffering from rare
genetic diseases.
Greenovation is the inventor of BryoTechnology, a nextgeneration platform that exploits the unique advantages
of the moss Physcomitrella patens for production of
highly effective biopharmaceuticals.
Today, Greenovation is a biopharmaceutical company
specialized in development of moss made therapeutics,
contract development and production as well as
licensing and technology transfer.
BryoTechnology: enables
delivery of a wide range of
products customized
according to the individual
needs of our clients
02 — 03
» Our vision is to provide
moss made biopharmaceuticals
that allow a safer and better
treatment of patients suffering
from orphan diseases.«
Dr. Thomas Frischmuth, CEO
GET OPTIMIZED
GLYCOSYLATION PATTERNS
YOU NEED
BryoEngineering:
rapid genome customization
in moss for development of
customized proteins
As moss is a higher eukaryote,
it possesses the enzymatic
machinery to carry out complex
posttranslational modifications like
glycosylations.
These moss enzymes, including chaperones and
glycosyltransferases are lined up along the secretory
pathway, which is the standard route used for
recombinant protein production by BryoTechnology.
Moss N-glycans are free of core α-1,6 -fucose, which drastically
increases the efficacy of IgG -products. This effect is
due to increased CD16 - binding and has great potential for
example in oncological applications.
GLYCOSYL
TRANSFERASES
DESIGNER
GLYCOSYLATION
04 — 05
TOXIN
TARGETS
TOXIN-RESISTANT
PRODUCTION
STRAINS
PROTEASES
PROTEASE-FREE
PRODUCTION
STRAINS
CUSTOMER
SPECIFIC GENES
CUSTOMER
SPECIFIC
Our BryoEngineering technology is straightforward:
Precise and stable genome modifications can be introduced
in Physcomitrella patens, this means that production
strains express human N-glycosylation while non-human
glycosylation with immunogenic potential is prevented.
The haplontic organism with its high rate of homologous
recombination along with knowledge of the fully sequenced
genome, allows for precise editing of any moss gene. The
customized platforms mean that specific proteins can be
produced quickly. The technology allows adaptations such
as protease knockouts or toxin-resistant ADC-production
platforms.
Greenovation offers the full range
from transient, small scale
production to process development of
biopharmaceutical production
in GMP-compliant, several hundred
litre wave bioreactors™.
06 — 07
SCALABLE PRODUCTION
OF HIGHLY EFFECTIVE
BIOPHARMACEUTICALS
Exploiting the unique advantages
of the moss Physcomitrella patens,
BryoTechnology is a next-generation
manufacturing technology for
production of a wide range of
biopharmaceuticals.
Greenovation’s moss-based technologies BryoSpeed®
and BryoMaster® include a wide range of advantages for
biopharmaceutical development and production processes.
Greenovation offers the full range from transient, small scale
production to process development of biopharmaceutical
production in GMP-compliant, several hundred litre wave
bioreactors™.
Bryo Master® – We offer the development of stable
production strains cultivated in a photoautotrophic
fermentation process for production of large scale batches.
Key attributes of BryoTechnology:
→ outstanding product quality with posttranslational modifications
→ batch-to-batch stability
→ excellent safety profile
→ virus and TSE-free production in
08 — 09
customizable strains
BryoSpeed® – We offer rapid delivery of initial, high
quality product samples, based on transiently transfected
protoplasts. Repeated harvesting yields µg to mg amounts
of high-quality, fully glycosylated product.
Regulatory compliance – We have created a cGMP-compliant
production process comparable to established production
strategies. Moss -based biopharmaceutical production is safe
and allows for straightforward technology transfer and
scale adaption.
TAKE ADVANTAGE
OF OUR TECHNOLOGY
AND KNOWLEDGE
Proprietary Drug Candidates
Our development pipeline includes proprietary drug
candidates for orphan diseases like Fabry Disease, Gaucher's
Disease, the atypical hemolytic uremic syndrome and Pompe
Disease. Our lead candidates moss-aGal and moss-GBA are
substitutes for human lysosomal enzymes, developed for
enzyme replacement therapy (ERT), which compensates for
a genetically-determined lack of an enzyme by regular infusion
of a biotechnologically-produced substitute.
WE ARE
LOOKING
FORWARD
TO
WORKING
WITH YOU
Contract Development & Production
Greenovation offers the full range of contract development
and manufacturing from transient protein productions to
customized drug substances and drug products using stable
cell lines. This allows our clients not only to test desired
protein products quickly, but also to access contract
manufactured biopharmaceuticals for clinical studies and
market supply.
Technology Transfer
Our moss-based technologies and IP portfolio cover plant
production processes, N-glycosylation techniques and
mechanisms-of-action. This has a wide range of advantages
for biopharmaceutical development and production
processes. We offer clients access to our BryoTechnology
platform and broad IP portfolio via a wide range of licensing
models. Alternatively, you can directly benefit from the
know-how and experience of our team at your production site.
10 — 11
Greenovation Biotech GmbH
Hans -Bunte -Str. 19
79108 Freiburg, Germany
Visit us at www. greenovation. com